Search

Background: Atherosclerosis is the most common cause of the cardiovascular disease. Saffron is a traditional food that affects many diseases and disorders. Therefore, the aim of this study was to identify the effects of Saffron (Crocus sativus L.) on quality of life (QOL) and appetite in patients with atherosclerosis. Materials and Methods: This was a randomized, double-blind, placebo-controlled clinical trial. A total of 63 participants with atherosclerosis were recruited from Emam Sajjad Hospital, Valiasr Hospital, and Zafaranieyh Clinic in Tehran, Iran. The participants were divided randomly into two groups. Participants received 100 mg/d saffron or placebo capsule for 6 weeks. QOL and appetite levels were measured by the McNew QOL questionnaire, and visual analog scale questionnaire, respectively. Furthermore, anthropometric indices of participants were measured before and after the intervention. Results: Statistical analysis showed that there was a statistically significant difference between atherosclerosis patients who received placebo and those who consumed saffron in terms of the physical domain (P = 0.008) and social domain (P = 0.012) of QOL. In the saffron group increased score in Total score Macnew (P < 0.001), physical domain (P = 0.025), and social domain (P < 0.001) was significant after the intervention. Moreover, the consumption of saffron did not significantly affect emotional domains of QOL, and appetite levels Conclusion: Saffron may be considered as a novel agent in patients with atherosclerosis to improve the QOL. A great deal of further research will be needed to critically validate the efficacy of saffron and its mechanisms in atherosclerosis. [ABSTRACT FROM AUTHOR]

Purpose: The aim of this study was to assess the effects of zinc supplementation on anthropometric measures, improving lipid profile biomarkers, and fasting blood glucose level in obese people. Methods: This randomized, double- blind clinical trial was carried out on 60 obese participants in the 18-45 age range for one month. The participants were randomly divided into the intervention group, who received 30 mg/d zinc gluconate, and the placebo group who received 30mg/d starch. Anthropometric measurements (body mass index (BMI), weight and waist circumference) were recorded before and at the end of study. Lipid profile biomarkers and fasting blood glucose were determined using enzymatic procedure. Analysis of Covariance (ANCOVA) test was run to compare the post-treatment values of the two groups, and t-test was conducted to compare within group changes. Results: Serum zinc concentration was increased significantly in intervention group (p=0.024). BMI and body weight was significantly decreased (p=0.030 and p=0.020, respectively). Lipid profile biomarkers and fating blood glucose did not change significantly but triglyceride level was significantly decreased (p=0.006) in the intervention group. Conclusion: The obtained results indicate that zinc supplementation improves BMI, body weight, and triglyceride concentration without considerable effects on lipid profile and glucose level. Zinc can be suggested as a suitable supplementation therapy for obese people, but more studies are needed to verify the results. [ABSTRACT FROM AUTHOR]